In the context of the multi-functionality of our products, an opportunity has developed to assess synergistic action between certain ESPA Biomedical products with cannabidiol (CBD).
Effects on the endocannabinoid system (ECS) is thought to become a focal point of the research and development of therapeutic agents.
Inflammation and impaired immune function are common biochemical targets for ESPA Biomedical products and CBD.
The project is to fulfill a great need to find more effective non-surgical and safe treatment modalities, utilizing multifunctional, herbal-based natural formulations developed by the ESPA Biomedical R&D team.
The project is conducted in association with internationally recognised clinical specialists.
- Anal fissure product is registered and approved by the Israel Ministry of Health
- Clinical trial in preparation
- Small scale production for trial in progress
- Estimated time to market by Q4 2020
The products on this website are not drugs and are not intended to diagnose, treat or prevent any disease.